ICML 2025
Jun 17 - 21, 2025 | Lugano, Switzerland
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma ModelsA Van Acker et al.